Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CTD402 |
| Synonyms | |
| Therapy Description |
CTD402 comprises T-lymphocytes that have been engineered with knockout of CD7, HLA-II, and TCR, and to express a chimeric antigen receptor (CAR) that targets CD7 and contains a 4-1BB co-stimulatory domain, a CD3zeta signaling domain, and a gammaC intracellular domain, which may lead to anti-tumor activity against CD7-expressing tumor cells (HemaSphere 2025; 9 (S1):431-432). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CTD402 | CTD 402|CTD-402 | CD7 Immune Cell Therapy 4 | CTD402 comprises T-lymphocytes that have been engineered with knockout of CD7, HLA-II, and TCR, and to express a chimeric antigen receptor (CAR) that targets CD7 and contains a 4-1BB co-stimulatory domain, a CD3zeta signaling domain, and a gammaC intracellular domain, which may lead to anti-tumor activity against CD7-expressing tumor cells (HemaSphere 2025; 9 (S1):431-432). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07070219 | Phase Ib/II | CTD402 | A Study of CTD402 in T-ALL/LBL Patients (TENACITY-01) | Recruiting | USA | 0 |